Oct 01, 2018
Virion Therapeutics, LLC Announces its Inaugural Board of Directors and Scientific Advisory Board Members
Sep 26, 2018
Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers
Sep 24, 2018
Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
Sep 21, 2018
Global DNA Vaccine Market Outlook 2018-2022: Increasing Investment, Dramatic Increase in Chronic Disorders, Strong DNA Vaccine Pipeline & Technological Advancements
Aug 06, 2018
Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health
Jul 31, 2018
Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection
Jul 30, 2018
SomaGenics Awarded Multi-Year Funding for Hepatitis Delta Virus Therapeutic Program
Jul 25, 2018
Hologic's Global Access Initiative Increases Availability of Diagnostic Testing in Resource-Limited Countries
Jul 05, 2018
ContraVir Pharmaceuticals to Present at Virtual Investor Conference
Jun 04, 2018
Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018(TM)
May 27, 2018
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
May 17, 2018
Profectus and Medisun Launch ProMed BioSciences to Develop and Commercialize Vaccines to Prevent and Treat Infectious Diseases and Cancer in Asian Countries
Apr 30, 2018
TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine
Apr 17, 2018
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress(TM) 2018
Apr 02, 2018
Eiger BioPharmaceuticals to Participate in Conferences in April
Mar 27, 2018
MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting
Mar 21, 2018
Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
Mar 12, 2018
MYR Pharma Completes Clinical Trial of Myrcludex B in Chronic Hepatitis Delta
Mar 05, 2018
Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress(TM) Meeting
Feb 22, 2018
MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B